

**ANNEX I**

**SUMMARY OF PRODUCT CHARACTERISTICS**

## **1. NAME OF THE MEDICINAL PRODUCT**

Cufence 100 mg hard capsules  
Cufence 200 mg hard capsules

## **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

### Cufence 100 mg hard capsules

Each hard capsule contains 150 mg trientine dihydrochloride equivalent to 100 mg trientine.

### Cufence 200 mg hard capsules

Each hard capsule contains 300 mg trientine dihydrochloride equivalent to 200 mg trientine.

For the full list of excipients see section 6.1.

## **3. PHARMACEUTICAL FORM**

Hard capsule.

### Cufence 100 mg hard capsules

White, oval-shaped size 3 capsule printed with 'Cufence 100' in grey ink.

### Cufence 200 mg hard capsules

White, oval-shaped size 0 capsule printed with 'Cufence' in grey ink.

## **4. CLINICAL PARTICULARS**

### **4.1 Therapeutic indications**

Cufence is indicated for the treatment of Wilson's disease in patients intolerant to D-Penicillamine therapy, in adults, adolescents and children aged 5 years or older.

### **4.2 Posology and method of administration**

Treatment should only be initiated by specialist physicians with experience in the management of Wilson's disease.

#### Posology

The starting dose would usually correspond to the lowest recommended dose and the dose should subsequently be adapted according to the patient's clinical response (see section 4.4).

The recommended dose is 800 – 1 600 mg daily in 2 to 4 divided doses.

The recommended doses of Cufence are expressed as mg of trientine base (i.e. not in mg of the trientine dihydrochloride salt) (see section 4.4).

#### Special populations

#### *Elderly*

There is insufficient clinical information available for Cufence to determine whether there exist differences in responses between the elderly and younger patients. In general, dose selection should be cautious, usually starting at the low end of the dosing range as recommended for adults, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other treatments.

#### *Renal impairment*

There is limited information in patients with renal impairment. Therefore, the recommended dose in patients with renal impairment is the same as for adults. For specific precautions see section 4.4.

#### *Hepatic impairment*

There is limited information in patients with hepatic impairment. Therefore, the recommended dose in patients with hepatic impairment is the same as for adults. For specific precautions see section 4.4.

#### *Patients primarily presenting hepatic symptoms*

The recommended dose in patients primarily presenting hepatic symptoms is the same as the recommended adult dose. It is advised, however, to monitor patients presenting with hepatic symptoms every two to three weeks after initiation of treatment with Cufence.

#### *Patients primarily presenting neurological symptoms*

Dose recommendations are the same as for adults. However, up titration should be done with moderation and consideration but can be initiated at the minimum available dose and adapted according to the patient's clinical response such as worsening of tremor as patients could be at risk of neurological deterioration at initiation of treatment (see section 4.4). It is further advised to monitor patients presenting with neurological symptoms every one to two weeks after initiation of treatment with Cufence until target dose is reached.

#### Paediatric population

The dose is lower than for adults and depends on age and body weight. The dose should be adjusted according to clinical response; 400 – 1 000 mg have been used at initiation of therapy (see section 4.4).

#### *Children < 5 years*

The safety and efficacy of Cufence in children aged 0 to 5 years have not yet been established. No data are available.

#### Method of administration

For oral use.

Capsules should be swallowed whole with water.

It is important that Cufence is given on an empty stomach, at least one hour before meals or two hours after meals, and at least one hour apart from any other medicinal product, food or milk (see section 4.5).

### **4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

### **4.4 Special warnings and precautions for use**

When switching a patient from another trientine formulation, caution is advised because different trientine salts are available which may have a different trientine content (base) and a different bioavailability. Dose adjustment may be required (see section 4.2).

Trientine is a chelating agent which has been found to reduce serum iron levels. Iron supplementation may be necessary in some cases. Concomitant oral iron should be administered at a different time than trientine (see section 4.5).

The combination of trientine with zinc is not recommended. There are only limited data on concomitant use available and no specific dose recommendations can be made.

There is no evidence that calcium and magnesium antacids alter the efficacy of trientine but it is recommended to separate their administration (see section 4.5).

In patients who were previously treated with D-Penicillamine, lupus-like reactions have been reported during subsequent treatment with trientine, however it is not possible to determine if there is a causal relationship with trientine.

### Monitoring

Patients receiving Cufence should remain under regular medical supervision and be monitored using all available clinical data for appropriate control of clinical symptoms and copper levels in order to optimise treatment. Frequency of monitoring is recommended to be at least twice a year. More frequent monitoring is advised during the initial phase of treatment and during phases of disease progression or when dose adjustments are made as to be decided by the treating physician (see section 4.2).

The aim of maintenance treatment is to maintain free copper levels in plasma (also known as non-ceruloplasmin plasma copper) and the urinary copper excretion within the acceptable limits.

The determination of serum free copper, calculated using the difference between the total copper and the ceruloplasmin-bound copper (normal level of free copper in the serum is usually 100 to 150 microgram/L), can be a useful index for monitoring therapy.

The measurement of copper excretion in the urine may be performed during therapy. Since chelation therapy leads to an increase in urinary copper levels, this may/will not give an accurate reflection of the excess copper load in the body but may be a useful measure of treatment compliance.

The use of appropriate copper parameter target ranges is described in clinical practice guidelines related to Wilson's disease.

Like with all anti-copper agents, overtreatment carries the risk of copper deficiency, which is especially harmful for children and pregnant women (see section 4.6) since copper is required for proper growth and mental development. Therefore, monitoring for manifestations of overtreatment should be undertaken.

Patients with renal and/or hepatic impairment receiving trientine should remain under regular medical supervision for appropriate control of symptoms and copper levels. Close monitoring of renal and/or liver function is also recommended in these patients (see section 4.2).

Worsening of neurological symptoms may occur at the beginning of chelation therapy due to excess of free serum copper during the initial response to treatment. It is possible that this effect may be more evident in patients with pre-existing neurological symptoms. It is recommended to monitor patients closely for such signs and symptoms and to consider careful titration to reach the recommended therapeutic dose and to reduce dose when necessary.

Dose adjustments in the trientine dose should be considered in case of signs of reduced efficacy such as (persistent) increase in liver enzymes, and worsening of tremor. When trientine doses are adjusted this should be done in small steps. The trientine dose may also be reduced in case of side effects of trientine, such as gastrointestinal complaints and haematological changes. Trientine doses should be

reduced to a more tolerable dose and may be increased again, once side effects have been resolved.

#### **4.5 Interaction with other medicinal products and other forms of interaction**

No interaction studies have been performed.

##### Zinc

There are insufficient data to support the concomitant use of zinc and trientine. The combination of trientine with zinc is not recommended as interaction of zinc with trientine is likely, thereby reducing the effect of both active substances.

##### Other anti-copper agents

No interaction studies have been performed on the concomitant administration of trientine with D-Penicillamine.

##### Food

Trientine is poorly absorbed following oral intake and food further inhibits trientine absorption. Specific food interaction studies have been performed with trientine in healthy subjects, showing a reduction of the extent of absorption of trientine up to 45%. Systemic exposure is critical for its principal mechanism of action, copper chelation (see section 5.1). Therefore, it is recommended that trientine is taken at least 1 hour before meals or 2 hours after meals and at least one hour apart from any other medicinal product, food, or milk to allow for maximum absorption and reduce the likelihood of the formation of complexes by metal binding in the gastrointestinal tract (see section 4.2).

##### Other products

Trientine has been found to reduce serum iron levels. Therefore, iron supplementation may be necessary in some cases. Concomitant oral iron or other heavy metals should be administered at a different time than trientine to prevent the formation of complexes (see section 4.4).

Although there is no evidence that calcium and magnesium antacids alter the efficacy of trientine, it is good practice to separate their administration (see section 4.4).

#### **4.6 Fertility, pregnancy and lactation**

##### Pregnancy

There is a limited amount of data from the use of trientine in pregnant women.

Studies in animals have shown reproductive toxicity, which was probably a result of trientine-induced copper deficiency (see section 5.3).

Trientine should be used in pregnancy only after careful consideration of the benefits compared with the risks of discontinuing treatment in the individual patient. Factors to consider include the known risks associated with untreated or undertreated Wilson's disease, risks associated with the stage of disease, the risk of those alternative treatments which are available and the possible effects of trientine (see section 5.3).

If treatment with trientine is to be continued following a risk-benefit analysis, consideration should be given to reducing the dose of trientine to the lowest effective dose and monitoring compliance with the treatment regimen.

The pregnancy should be closely monitored in order to detect possible foetal abnormality and to assess maternal serum copper levels throughout the pregnancy. The dose of trientine used should be adjusted

in order to maintain serum copper levels within the normal range. Since copper is required for proper growth and mental development, dose adjustments may be required to ensure that the foetus will not become copper deficient and close monitoring of the patient is essential (see section 4.4)

Babies born to mothers being treated with trientine should be monitored for serum copper and ceruloplasmin levels where appropriate.

#### Breast-feeding

There is limited clinical data suggesting that trientine is not excreted in breast milk. However, a risk to the newborns/infants cannot be excluded.

A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from trientine therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

#### Fertility

It is unknown whether trientine has an effect on human fertility.

### **4.7 Effects on ability to drive and use machines**

Trientine has no or negligible influence on the ability to drive and use machines.

### **4.8 Undesirable effects**

#### Summary of the safety profile

Nausea can commonly occur on initial treatment and occasionally skin rash can occur. Duodenitis and severe colitis have been reported. Neurological deterioration can occur at the start of the treatment.

#### Tabulated list of adverse reactions

Table 1. is according to the MedDRA system organ classification (SOC and Preferred Term Level). Frequencies are defined as: very common ( $\geq 1/10$ ); common ( $\geq 1/100$  to  $< 1/10$ ); uncommon ( $\geq 1/1000$  to  $< 1/100$ ); rare ( $\geq 1/10000$  to  $< 1/1000$ ); very rare ( $< 1/10000$ ); not known (cannot be estimated from the available data).

**Table 1. Adverse reactions**

MedDRA- system organ class database	Adverse reaction
Blood and lymphatic system disorders:	Uncommon: Anaemia
	Uncommon: Aplastic anaemia
	Uncommon: Sideroblastic anaemia
Immune system disorders:	Not known: Lupus-like syndrome
	Not known: Lupus nephritis
Nervous system disorders:	Uncommon: Dystonia
	Uncommon: Tremor
	Not known: Dysarthria
	Not known: Muscle rigidity
	Not known: Neurological deterioration
Gastrointestinal disorders:	Common: Nausea
	Not known: Colitis

MedDRA- system organ class database	Adverse reaction
	Not known: Duodenitis
Skin and subcutaneous tissue disorders:	Uncommon: Rash

#### Description of selected adverse reactions

There have been reports of neurological deterioration at the start of treatment in Wilson's disease patients treated with copper chelators including trientine, with symptoms of, for example, dystonia, rigidity, tremor and dysarthria (see section 4.2).

#### Paediatric population

Clinical studies with Cufence including a limited number of children in the age range of 5 to 17 years at the start of treatment indicate that frequency, type and severity of adverse reactions in children are expected to be the same as in adults.

#### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in [Appendix V](#).

### **4.9 Overdose**

Occasional cases of trientine overdose have been reported. In cases up to 20 g of trientine base there were no apparent adverse effects reported. A large overdose of 40 g of trientine base resulted in self-limiting dizziness and vomiting with no other clinical sequelae or significant biochemical abnormalities reported.

In the event of overdose the patient should be observed, appropriate biochemical analysis performed and symptomatic treatment given. There is no antidote.

Chronic overtreatment can lead to copper deficiency and reversible sideroblastic anaemia. Overtreatment and excess copper removal can be monitored using values of urine copper excretion and of non-ceruloplasmin bound copper. Close monitoring is required to optimise the dose or adapt treatment if necessary (see section 4.4).

## **5. PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Other alimentary tract and metabolism, various alimentary tract and metabolism products, ATC code: A16AX12

#### Mechanism of action

Trientine is a copper-selective chelator that enhances systemic elimination of divalent copper by forming a stable complex that is readily excreted by the kidneys. Trientine is a chelator with a polyamine-like structure and copper is chelated by forming a stable complex with the four constituent nitrogens in a planar ring. Thus, the pharmacodynamic action of trientine is dependent on its chemical property of chelating copper and not on its interaction with receptors, enzyme systems or any other biological system that might differ between species. Trientine may also chelate copper in the intestinal tract and so inhibit copper absorption.

### **5.2 Pharmacokinetic properties**

## Absorption

The bioavailability of trientine capsules in human beings has not been established. Based on preclinical data, the mechanism of absorption and the high first pass effect, it is expected that trientine bioavailability is low and highly variable following oral administration. Clinical studies showed that trientine is absorbed with  $t_{max}$  occurring between 0.5 and 6 hours post-dose in healthy volunteers and patients. Exposure to trientine is highly variable between subjects, with a variation of up to 60%.

The intake of food within 30 minutes prior to trientine administration delays the time to peak concentrations by 2 hours and reduces the extent of absorption of trientine by approximately 45%.

## Distribution

Trientine has low human plasma protein binding and is widely distributed in tissues with relatively high concentrations measured in liver, heart, and kidney in the rat.

## Biotransformation

Trientine is acetylated in two major metabolites, N(1)-acetyltriethylenetetramine (MAT) and N(1),N(10)-diacetyltriethylenetetramine (DAT). Clinical data in healthy subjects indicate that the plasma exposure to the MAT metabolite is approximately 3 times that of unchanged trientine, while exposure to the DAT metabolite is slightly lower compared to trientine. The metabolites of trientine have Cu-chelating properties, however the stability of these Cu-complexes is low due to the introduction of the acetyl groups. Clinical data in healthy volunteers suggest limited contribution of chelating activity by the MAT and DAT metabolites. The extent of MAT and DAT's contribution to the overall effect of Cufence on copper levels in Wilson's Disease patients remains to be determined.

Trientine is metabolised by acetylation via spermidine/spermine N-acetyltransferase and not via N-acetyltransferase 2.

## Elimination

After absorption trientine and its metabolites are rapidly excreted in the urine, either bound to copper or unbound. The unabsorbed fraction of orally administered trientine is bound to intestinal copper and eliminated through faecal excretion.

The elimination half-life of trientine is approximately 4 hours (mean  $t_{1/2}$  of  $3.8 \pm 1.3$  hours measured at steady state in WD patients and  $4.4 \pm 4.7$  hours measured after a single dose in healthy volunteers).

The elimination half-lives of the two metabolites were  $14.1 \pm 3.7$  hours for MAT and  $8.5 \pm 3.0$  hours for DAT after a single dose administration of trientine in healthy subjects.

## Special populations

### *Age /gender/body weight*

Data from clinical studies conducted in adult healthy subjects indicate that age, gender and body weight do not seem to influence the pharmacokinetics of trientine.

### Ethnicity

No pharmacokinetic analysis has been performed on interethnic differences.

## **5.3 Preclinical safety data**

Non-clinical data reveal no special hazard for humans based on a series of studies investigating cardiovascular safety pharmacology, repeated dose toxicity, genotoxicity and toxicity to embryofoetal



development.

Effects in non-clinical studies were largely consistent with induced copper deficiency in the plasma and liver of previously copper normative animals and as such could be attributed to the pharmacological action of trientine. The main toxicological findings associated with trientine, which were generally seen across all species examined, included body weight loss or lower body weight gain, altered urinary electrolytes, low plasma copper levels and various histopathological changes in the lungs (mainly interstitial pneumonitis). All effects were reversible with the exception of the lung findings; however the dose levels where these effects were observed are far in excess of those used clinically. Moreover, there was some doubt about the relationship to trientine, as the lung findings were also observed in most of the control dogs in the 26 week study. In dogs, ataxia, tremors, abnormal gait and underactivity were observed following administration of very high levels of trientine. Some functional neurological abnormalities were also identified, particularly in severely affected animals, however no associated nerve damage was observed. Electrocardiography was also unaffected.

In pregnant animals, high dose trientine associated with significant reductions in serum copper, revealed an early effect on embryo survival and a marginally lower foetal weight. There was no evidence of embryo-foetal toxicity at lower dose levels despite dose-related reductions in serum copper. These effects were observed only at exposures sufficiently in excess of maximum human exposure to indicate little relevance to clinical use.

No fertility data are available but estrous cyclicity was unaffected and reproductive organs were not identified as target organs in general repeat dose toxicity studies.

The OECD SIDS triethylenetetramine 2002 classifies the genotoxic profile of trientine as low priority/concern. Some positive *in vitro* mutagenicity data were obtained but *in vivo* test systems showed no mutagenic activity. No long term animal carcinogenicity trials have to date been performed with trientine via the oral route, but via the dermal route, there was no increases in cancers above baseline. Moreover, there is evidence to suggest that trientine actually reduces endogenous DNA damage in a strain of rat (Long-Evans Cinnamon) considered to represent an appropriate model of Wilson's disease. This suggests a reduced carcinogenic risk for Wilson's disease patients as a result of trientine therapy.

Trientine dihydrochloride is a known irritant, especially to mucus membranes, upper respiratory tract and skin, and induces skin sensitisation in guinea pigs, mice and man (OECD SIDS triethylenetetramine 2002).

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

#### Capsule content

Magnesium stearate  
Colloidal anhydrous silica

#### Capsule shell

Gelatin  
Titanium dioxide (E171)

#### Printing ink

Shellac  
Propylene glycol (E1520)

Titanium dioxide (E171)  
Iron oxide black (E172)  
Iron oxide yellow (E172)

## **6.2 Incompatibilities**

Not applicable.

## **6.3 Shelf life**

3 years.

After first opening the bottle: 3 months.

## **6.4 Special precautions for storage**

Keep the bottle tightly closed in order to protect from moisture.

## **6.5 Nature and contents of container**

### Cufence 100 mg hard capsules

White opaque HDPE bottle with an HDPE child-resistant screw cap and induction heat seal liner with a sachet of dried silica gel as desiccant.

Pack size: 1 bottle of 200 hard capsules.

### Cufence 200 mg hard capsules

Amber glass bottle with a polypropylene cap and induction heat seal liner with a sachet of dried silica gel as desiccant.

Pack size: 1 bottle of 100 hard capsules.

Not all pack-sizes may be marketed.

## **6.6 Special precautions for disposal**

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Univar Solutions BV  
Schouwburgplein 30  
3012 CL Rotterdam  
The Netherlands

## **8. MARKETING AUTHORISATION NUMBER(S)**

EU/1/19/1365/002  
EU/1/19/1365/001

## **9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 25 July 2019  
Date of latest renewal: 16 May 2024

## **10. DATE OF REVISION OF THE TEXT**

Detailed information on this medicinal product is available on the website of the European Medicines Agency <https://www.ema.europa.eu>.

## **ANNEX II**

- A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**
- D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**

## **A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**

### Name and address of the manufacturer responsible for batch release

Aesica Pharmaceuticals GmbH  
Alfred Nobel Strasse 10  
Monheim 40789  
Germany

## **B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## **C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

- **Periodic safety update reports (PSURs)**

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## **D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**

- **Risk management plan (RMP)**

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
- **Obligation to conduct post-authorisation measures**

The MAH shall complete, within the stated timeframe, the below measures:

Description	Due date
PAES: In order to further characterise the efficacy of trientine dihydrochloride in the treatment of Wilson's disease in patients with predominantly hepatic, neurologic or psychiatric symptoms as well as in paediatric patients, the MAH should conduct and submit the results of an open label, prospective study to investigate the clinical course of hepatic, neurological and psychiatric disease from the time of initiation of treatment with trientine dihydrochloride up to 24 months of therapy. The study will also contain a PK/PD sub-study to evaluate the dose-response relationship especially during the up-titration phase. The study should be conducted according to an agreed protocol.	Final report: Q4 2026 (main study)

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**CARTON**

**1. NAME OF THE MEDICINAL PRODUCT**

Cufence 100 mg hard capsules  
trientine

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each hard capsule contains 150 mg trientine dihydrochloride, equivalent to 100 mg trientine.

**3. LIST OF EXCIPIENTS**

**4. PHARMACEUTICAL FORM AND CONTENTS**

Hard capsule.  
200 hard capsules

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.

Oral use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP  
After first opening, use within 3 months.

Open date\_\_\_\_\_

**9. SPECIAL STORAGE CONDITIONS**

Keep the bottle tightly closed in order to protect from moisture.



<b>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</b>
--

<b>11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b>
---

Univar Solutions BV  
Schouwburgplein 30  
3012 CL Rotterdam  
The Netherlands

<b>12. MARKETING AUTHORISATION NUMBER(S)</b>
--

EU/1/19/1365/002

<b>13. BATCH NUMBER</b>
-------------------------

Lot

<b>14. GENERAL CLASSIFICATION FOR SUPPLY</b>
--

<b>15. INSTRUCTIONS ON USE</b>
--------------------------------

<b>16. INFORMATION IN BRAILLE</b>
-----------------------------------

Cufence 100 mg

<b>17. UNIQUE IDENTIFIER – 2D BARCODE</b>
---

2D barcode carrying the unique identifier included.

<b>18. UNIQUE IDENTIFIER - HUMAN READABLE DATA</b>
--

PC  
SN  
NN

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING****BOTTLE****1. NAME OF THE MEDICINAL PRODUCT**

Cufence 100 mg hard capsules  
trientine

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each hard capsule contains 150 mg trientine dihydrochloride, equivalent to 100 mg trientine.

**3. LIST OF EXCIPIENTS****4. PHARMACEUTICAL FORM AND CONTENTS**

Hard capsule.  
200 hard capsules

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.

Oral use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY****8. EXPIRY DATE**

EXP  
After first opening, use within 3 months.

**9. SPECIAL STORAGE CONDITIONS**

Keep the bottle tightly closed in order to protect from moisture.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Univar Solutions BV  
Schouwburgplein 30  
3012 CL Rotterdam  
The Netherlands

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/19/1365/002

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

**17. UNIQUE IDENTIFIER – 2D BARCODE**

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**CARTON**

**1. NAME OF THE MEDICINAL PRODUCT**

Cufence 200 mg hard capsules  
trientine

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each hard capsule contains 300 mg trientine dihydrochloride, equivalent to 200 mg trientine.

**3. LIST OF EXCIPIENTS**

**4. PHARMACEUTICAL FORM AND CONTENTS**

Hard capsule.  
100 hard capsules

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.

Oral use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP  
After first opening, use within 3 months.

Open date\_\_\_\_\_

**9. SPECIAL STORAGE CONDITIONS**

Keep the bottle tightly closed in order to protect from moisture.

<b>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</b>
--

<b>11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b>
---

Univar Solutions BV  
Schouwburgplein 30  
3012 CL Rotterdam  
The Netherlands

<b>12. MARKETING AUTHORISATION NUMBER(S)</b>
--

EU/1/19/1365/001

<b>13. BATCH NUMBER</b>
-------------------------

Lot

<b>14. GENERAL CLASSIFICATION FOR SUPPLY</b>
--

<b>15. INSTRUCTIONS ON USE</b>
--------------------------------

<b>16. INFORMATION IN BRAILLE</b>
-----------------------------------

Cufence 200 mg

<b>17. UNIQUE IDENTIFIER – 2D BARCODE</b>
---

2D barcode carrying the unique identifier included.

<b>18. UNIQUE IDENTIFIER - HUMAN READABLE DATA</b>
--

PC  
SN  
NN

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING****BOTTLE****1. NAME OF THE MEDICINAL PRODUCT**

Cufence 200 mg hard capsules  
trientine

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each hard capsule contains 300 mg trientine dihydrochloride, equivalent to 200 mg trientine.

**3. LIST OF EXCIPIENTS****4. PHARMACEUTICAL FORM AND CONTENTS**

Hard capsule.  
100 hard capsules

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.

Oral use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY****8. EXPIRY DATE**

EXP  
After first opening, use within 3 months.

**9. SPECIAL STORAGE CONDITIONS**

Keep the bottle tightly closed in order to protect from moisture.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS**

**OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Univar Solutions BV  
Schouwburgplein 30  
3012 CL Rotterdam  
The Netherlands

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/19/1365/001

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

**17. UNIQUE IDENTIFIER – 2D BARCODE**

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

## **B. PACKAGE LEAFLET**



## **Package leaflet: Information for the patient**

**Cufence 100 mg hard capsules**

**Cufence 200 mg hard capsules**

trientine

**Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.**

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

### **What is in this leaflet**

1. What Cufence is and what it is used for
2. What you need to know before you take Cufence
3. How to take Cufence
4. Possible side effects
5. How to store Cufence
6. Contents of the pack and other information

#### **1. What Cufence is and what it is used for**

Cufence is a medicine used for the treatment of Wilson's disease in adults, adolescents and children aged 5 years or older. It is for use by patients who cannot take another medicine, D-Penicillamine, because of side effects.

Cufence contains the active substance trientine, a copper-chelating agent that is used to remove excess of copper from the body. Cufence attaches to the copper, which is then passed from the body.

#### **2. What you need to know before you take Cufence**

##### **Do not take Cufence**

If you are allergic to trientine or any of the other ingredients of this medicine (listed in section 6).

Signs of an allergic reaction include rash, itching, swelling of the face, fainting and breathing problems.

##### **Warnings and precautions**

Your doctor will need to regularly check for symptoms of the disease and copper levels in your blood and urine. Regular monitoring is especially important at the start of your treatment or when your dose is changed, in growing children and pregnant women to ensure that copper levels are maintained at a suitable level. The doctor may need to increase or decrease your dose of Cufence.

Nervous system problems can occur (for example, shaking, lack of coordination, slurred speech, muscle stiffness and worsening of muscle spasms), especially in patients just starting treatment with Cufence. If you notice these whilst taking Cufence, you must tell your doctor immediately.

Lupus-like reactions (symptoms may include persistent rash, fever, joint pain, and tiredness) have been reported in some patients switched to trientine medicine after penicillamine medicine. However,

it was not possible to determine if the reaction was due to trientine or to previous penicillamine treatment.

### **Other medicines and Cufence**

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

If you are taking iron tablets or medicines that neutralise the acid in your stomach, leave at least 2 hours before or after you have taken Cufence because they may reduce Cufence's effect. It is recommended that trientine is taken at least one hour apart from any other medicinal product.

### **Cufence with food and drink**

Take this medicine with water only. Do not take it with other drinks, milk or food because they may reduce the medicine's effect. Avoid eating or drinking (except water) for 2 hours before and 1 hour after taking Cufence.

### **Pregnancy and breast-feeding**

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. It is very important to continue treatment to maintain normal copper levels during pregnancy. You and your doctor should fully discuss the potential benefits of treatment whilst considering any possible risks that there may be. Your doctor will advise you which treatment and which dose is best in your situation. If you become pregnant whilst taking Cufence, talk to your doctor.

If you are pregnant and taking Cufence, you will be monitored throughout your pregnancy for any effects on the baby or changes in your copper levels.

The limited information available suggests that Cufence does not pass into breast milk, but it is not certain that there is no risk to the baby. It is important to tell your doctor if you are breast-feeding or plan to do so. Your doctor will then help you decide whether to stop breast-feeding or to stop taking Cufence, considering the benefit of breast-feeding to the baby and the benefit of Cufence to the mother. Your doctor will decide which treatment and which dose is best in your situation.

### **Driving and using machines**

Trientine is not likely to have an effect on your ability to drive or use machines.

## **3. How to take Cufence**

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

### Adults (including the elderly)

The usual dose is between 800 and 1 600 mg per day, to be taken by mouth.

### Use in children and adolescents (5 to 17 years)

In children and adolescents, the dose depends on age and body weight and will be adjusted by your doctor. At the start of treatment the dose varies between 400 and 1 000 mg per day.

### Method of administration

Your doctor will decide the correct dose for you.

The total daily dose can be divided into 2 to 4 smaller doses, as indicated by your doctor. Swallow the capsules whole with a drink of water on an empty stomach, at least 1 hour before or 2 hours after food.

Patients who have difficulties swallowing should contact their doctor.

### **If you take more Cufence than you should**

If you take more medicine than you should, you may get nausea, vomiting and dizziness. You must contact your doctor or another health care provider immediately.

### **If you forget to take Cufence**

If you forget to take a dose take your next dose at its usual scheduled time.

Do not take a double dose to make up for a forgotten dose.

### **If you stop taking Cufence**

This medicine is for long-term use because Wilson's disease is a life-long condition. Do not stop or change your treatment without speaking with your doctor even if you feel better.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist

## **4. Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Occasionally (frequency unknown; cannot be estimated from available data), treatment with this medicine can cause inflammation of the small intestine or colon. If you have any of the following side effects contact your doctor **immediately**:

- Severe stomach pains
- Persistent diarrhoea
- Nervous system problems (for example shaking, lack of coordination, slurred speech, muscle stiffness, worsening of muscle spasms).

Other side effects may include:

**Common** (may affect up to 1 in 10 people)

- Nausea (especially when starting treatment)

**Uncommon** (may affect up to 1 in 100 people)

- Skin rashes
- Anaemia (you may feel unusually tired)

### **Reporting of side effects**

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in [Appendix V](#). By reporting side effects, you can help provide more information on the safety of this medicine.

## **5. How to store Cufence**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the bottle label and outer carton after EXP. The expiry date refers to the last day of the month.

Use within 3 months after first opening the bottle. Keep the bottle tightly closed in order to protect from moisture. Do not use if the capsules become sticky or wet.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

## **6. Contents of the pack and other information**

### **What Cufence contains**

The active substance is trientine.

- Each hard capsule of Cufence 100mg contains 150 mg trientine dihydrochloride, equivalent to 100 mg trientine.
- Each hard capsule of Cufence 200 mg contains 300 mg trientine dihydrochloride, equivalent to 200 mg trientine.

The other ingredients are

- Capsule content: Magnesium stearate, colloidal anhydrous silica
- Capsule shell: Gelatin, titanium dioxide (E171)
- Printing ink: Shellac, propylene glycol (E1520), titanium dioxide (E171), iron oxide black (E172), iron oxide yellow (E172)

### **What Cufence looks like and contents of the pack**

#### Cufence 100 mg hard capsules

White opaque HDPE bottle with an HDPE child-resistant screw cap and induction heat seal liner with a sachet of dried silica gel as desiccant. Each hard capsule is white oval-shaped size 3 (15.8 mm x 5.85 mm) with 'Cufence 100' printed in grey ink.

Pack size: one bottle of 200 hard capsules.

#### Cufence 200 mg hard capsules

Amber glass bottle with a polypropylene cap and induction heat seal liner with a sachet of dried silica gel as desiccant. Each hard capsule is white oval-shaped size 0 (21.8 mm x 7.66 mm) with 'Cufence' printed in grey ink.

Pack size: one bottle of 100 hard capsules.

Not all pack-sizes may be marketed.

### **Marketing Authorisation Holder**

Univar Solutions BV  
Schouwburgplein 30  
3012 CL Rotterdam  
The Netherlands

### **Manufacturer**

Aesica Pharmaceuticals GmbH  
Alfred-Nobel Strasse 10  
40789 Monheim  
Germany

**This leaflet was last revised in .**

### **Other sources of information**

Detailed information on this medicine is available on the European Medicines Agency web site:  
<https://www.ema.europa.eu>. There are also links to other websites about rare diseases and treatments.